To determine how functional precision medicine assays can identify patients with relapsed/refractory soft tissue sarcoma who are likely to benefit from bortezomib therapy.
Utilized functional precision medicine assays to assess patient tumors
Evaluated response to bortezomib-based treatment
Monitored side effects including mucositis and hyperglycemia
Identified a subset of patients responding positively to bortezomib
Reported significant side effects like mucositis and hyperglycemia in some cases
Abstract
5%.Other G1/2: mucositis 37.5%, hyperglycemia 37
问 AI
Like
Bookmark
Share
View Full Paper
问 AI
Like
Bookmark
Share
View Full Paper
172P Functional precision medicine assay identifies patients with relapsed/refractory soft tissue sarcoma who benefit from bortezomib-based therapy | Synapse